<DOC>
	<DOCNO>NCT00470184</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy together radiation therapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give oxaliplatin capecitabine together radiation therapy work treat patient undergo surgery stage II , stage III , stage IV esophageal cancer .</brief_summary>
	<brief_title>Oxaliplatin , Capecitabine , Radiation Therapy Patients Undergoing Surgery Stage II , III , IV Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete pathologic response ( complete response [ CR ] ) rate patient stage II-IVA esophageal cancer treat neoadjuvant oxaliplatin , capecitabine , radiotherapy . Secondary - Determine clinical efficacy toxicity regimen patient . - Determine quality life patient treat regimen . - Identify basal expression change gene expression relate CR , relapse , survival patient treat regimen . OUTLINE : - Neoadjuvant chemoradiotherapy : Patients receive oxaliplatin IV 2 hour day 1 , 15 , 29 ( week 1 , 3 , 5 ) . Patients also undergo radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-38 receive oral enteral capecitabine twice daily day undergo radiotherapy . - Surgery : At 4-6 week completion neoadjuvant chemoradiotherapy , patient eligible undergo esophagectomy . - Adjuvant chemotherapy : Beginning 4-6 week surgery , patient receive oxaliplatin IV 2 hour day 1 , 15 , 29 oral enteral capecitabine twice daily day 1-5 , 8-12 , 15-19 , 22-26 , 29 . Treatment repeat approximately every 14 day 2 course absence disease progression unacceptable toxicity . Patients undergo tumor biopsy periodically . Collected sample analyze gene expression study , microarray analysis , real-time quantitative reverse transcriptase-PCR identify basal expression change gene expression . Quality life assess periodically . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis squamous cell carcinoma esophagus adenocarcinoma esophagus Stage IIIVA disease determine clinical staging , include endoscopy CT scan without endoscopic ultrasound Bulk gastroesophageal junction tumor esophagus Bronchoscopy biopsy cytology require primary esophageal cancer &lt; 26 cm incisor No know brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 4 month WBC &gt; 4,000/mm³ ANC &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 9 g/dL Bilirubin normal Creatinine normal AST &lt; 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN Able take oral medication undergo enteral administration medication No peripheral neuropathy ≥ grade 2 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 90 day completion study treatment No hypersensitivity platinum compound , fluoropyrimidines , antiemetic administer combination protocoldirected chemotherapy No concurrent uncontrolled illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study compliance No history second malignancy except curatively treat carcinoma situ cervix nonmelanoma skin cancer Other cure tumor allow discretion principal investigator No known HIV hepatitis B C ( active and/or previously treat ) PRIOR CONCURRENT THERAPY : No prior therapy esophageal cancer No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>